ES2150941T3 - Aminas biciclicas-heterociclicas eficaces farmaceuticamente. - Google Patents

Aminas biciclicas-heterociclicas eficaces farmaceuticamente.

Info

Publication number
ES2150941T3
ES2150941T3 ES93908303T ES93908303T ES2150941T3 ES 2150941 T3 ES2150941 T3 ES 2150941T3 ES 93908303 T ES93908303 T ES 93908303T ES 93908303 T ES93908303 T ES 93908303T ES 2150941 T3 ES2150941 T3 ES 2150941T3
Authority
ES
Spain
Prior art keywords
heterociclic
amines
pharmaceutically effective
bicycle
effective bicycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908303T
Other languages
English (en)
Inventor
Donald E Ayer
Gordon L Bundy
Eric Jon Jacobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2150941T3 publication Critical patent/ES2150941T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTAN LOS AMINOS BICICLICOS-HETEROCICLICOS FARMACOLOGICAMENTE ACTIVOS (XXX), DONDE W1 ES N= O -CH=; W3 ES -N= O -CH=; W5 ES -.N= O -CR5ANDO TANTO W1 COMO W3 SEAN -N=, LOS COMPUESTOS SON UTILES COMO PRODUCTOS FARMACEUTICOS EN EL TRATAMIENTO DE LESIONES DE CABEZA LEVES Y/O DE MODERADAS A SEVERAS, HEMORRAGIAS SUBARACNOIDES Y EL SUBSECUENTE CHOQUE ISQUEMICO, EL ASMA Y LA REDUCCION DE LA FORMACION/SECRECION DE MUCOSIDAD EN EL PULMON Y OTRAS ENFERMEDADES Y LESIONES.
ES93908303T 1992-04-03 1993-03-16 Aminas biciclicas-heterociclicas eficaces farmaceuticamente. Expired - Lifetime ES2150941T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86364692A 1992-04-03 1992-04-03

Publications (1)

Publication Number Publication Date
ES2150941T3 true ES2150941T3 (es) 2000-12-16

Family

ID=25341481

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908303T Expired - Lifetime ES2150941T3 (es) 1992-04-03 1993-03-16 Aminas biciclicas-heterociclicas eficaces farmaceuticamente.

Country Status (21)

Country Link
EP (1) EP0633886B1 (es)
JP (1) JPH08502721A (es)
KR (1) KR100284473B1 (es)
AT (1) ATE197051T1 (es)
AU (1) AU675932B2 (es)
CA (1) CA2130937A1 (es)
CZ (1) CZ236494A3 (es)
DE (1) DE69329574T2 (es)
DK (1) DK0633886T3 (es)
ES (1) ES2150941T3 (es)
FI (1) FI944602L (es)
GR (1) GR3035188T3 (es)
HU (1) HUT70954A (es)
LV (1) LV12794B (es)
MX (1) MX9301847A (es)
NO (1) NO303542B1 (es)
PL (2) PL175327B1 (es)
PT (1) PT633886E (es)
RU (1) RU2103272C1 (es)
SK (1) SK119194A3 (es)
WO (1) WO1993020078A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU694853B2 (en) * 1995-03-02 1998-07-30 Pharmacia & Upjohn Company Pyrimido{4,5-b}indoles
US5753635A (en) * 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
CN1246856A (zh) 1996-11-19 2000-03-08 安姆根有限公司 芳基和杂芳基取代的稠合吡咯抗炎药
WO1998024453A1 (en) * 1996-12-05 1998-06-11 Nippon Shinyaku Co., Ltd. Remedies for myelopathy
EP0964865B1 (en) * 1997-01-08 2003-03-05 PHARMACIA & UPJOHN COMPANY Pharmaceutically active tricyclic amines
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB2331988B (en) * 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
HUP0103836A3 (en) * 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CA2342855A1 (en) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyranoses
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
KR100840727B1 (ko) 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
EP1244672B1 (en) 1999-12-21 2005-07-20 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
AU2001270783B2 (en) * 2000-07-11 2006-06-15 Pharma Mar, S.A. Variolin derivatives as anti-cancer agents
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
SE0003795D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
DE60234118D1 (de) 2001-11-30 2009-12-03 Osi Pharm Inc Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
ATE458483T1 (de) 2001-12-20 2010-03-15 Osi Pharm Inc Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
US20070185217A1 (en) * 2003-12-23 2007-08-09 Abraxis Bioscience, Inc. Propofol analogs, process for their preparation, and methods of use
JP5078350B2 (ja) * 2004-03-04 2012-11-21 キッセイ薬品工業株式会社 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
CA2570693A1 (en) 2004-06-17 2006-01-26 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
WO2006009734A1 (en) 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
KR20070028553A (ko) 2004-06-18 2007-03-12 바이올리폭스 에이비 염증 치료에 유용한 인돌
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
AU2005325497A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
FR2884824B1 (fr) 2005-04-20 2007-07-13 Sanofi Aventis Sa Derives de 1h-pyrimido[4,5-b]indole, leur preparation et leur application en therapeutique
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
KR100749216B1 (ko) * 2006-08-30 2007-08-13 위아 주식회사 4륜구동차량용 부변속기
CA2668959A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
ES2424977T3 (es) * 2007-08-08 2013-10-10 Glaxosmithkline Intellectual Property Development Limited Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
CN101784543B (zh) * 2007-08-17 2013-10-16 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚和吲唑化合物
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
ES2430621T3 (es) 2008-01-31 2013-11-21 Sanofi Azaindol-3-carboxamidas cíclicas, su preparación y su uso como productos farmacéuticos
TW200938201A (en) * 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
JP5877064B2 (ja) * 2008-11-11 2016-03-02 エックスカバリー ホールディング カンパニー エルエルシー ＰＩ３Ｋ／ｍＴＯＲキナーゼ阻害剤
EP3170813B1 (en) 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazole derivatives as pi3 kinase inhibitors
SG192193A1 (en) 2011-01-31 2013-09-30 Novartis Ag Novel heterocyclic derivatives
PH12013501800A1 (en) 2011-03-15 2013-10-14 L Livermore Nat Security Llc Tricyclic gyrase inhibitors
AP2014007601A0 (en) 2011-10-28 2014-04-30 Novartis Ag Novel purine derivatives and their use in the treatment of disease
SMT201900360T1 (it) 2012-01-27 2019-07-11 Univ Montreal DERIVATI DI PIRIMIDO[4,5-b]INDOLO E LORO UTILIZZO NELL'ESPANSIONE DELLE CELLULE STAMINALI EMATOPOIETICHE
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2015137887A1 (en) * 2014-03-13 2015-09-17 Agency For Science, Technology And Research Fused pyrimidine-based hydroxamate derivatives
AU2015321654B2 (en) * 2014-09-22 2019-10-31 National Health Research Institutes Heterocyclic compounds and use thereof
US10828329B2 (en) 2015-06-05 2020-11-10 Hema-Quebec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
MX377305B (es) 2015-09-14 2025-03-07 Pfizer DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CA3034010A1 (en) 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
MX2020008265A (es) * 2018-02-16 2020-09-21 UCB Biopharma SRL Derivados farmaceuticos del anillo heterobiciclico 6,5.
CN114040760B (zh) * 2018-12-31 2025-05-09 拜欧米富士恩公司 Menin-mll相互作用的不可逆抑制剂
EP4161519A4 (en) * 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. PURINES AND METHODS OF USE
US20230234943A1 (en) * 2020-06-26 2023-07-27 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864145A (en) * 1959-06-02 1961-03-29 Thomae Gmbh Dr K Novel purines and a process for their manufacture
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
ATE140457T1 (de) * 1989-09-19 1996-08-15 Teijin Ltd Pyrrolo(2,3-d>pyrimidinderivate, verfahren zur herstellung und arzneimittelzusammensetzungen die diese enthalten

Also Published As

Publication number Publication date
PT633886E (pt) 2001-03-30
KR950700912A (ko) 1995-02-20
RU2103272C1 (ru) 1998-01-27
RU94042466A (ru) 1996-07-20
JPH08502721A (ja) 1996-03-26
HU9402829D0 (en) 1995-02-28
GR3035188T3 (en) 2001-04-30
EP0633886A1 (en) 1995-01-18
FI944602A7 (fi) 1994-10-03
CA2130937A1 (en) 1993-10-14
LV12794B (lv) 2002-06-20
FI944602A0 (fi) 1994-10-03
KR100284473B1 (ko) 2001-04-02
NO943655D0 (no) 1994-09-30
NO303542B1 (no) 1998-07-27
MX9301847A (es) 1993-10-01
LV12794A (en) 2002-02-20
DE69329574D1 (de) 2000-11-23
AU675932B2 (en) 1997-02-27
CZ236494A3 (en) 1994-12-15
EP0633886B1 (en) 2000-10-18
PL175347B1 (pl) 1998-12-31
DE69329574T2 (de) 2001-05-31
PL175327B1 (pl) 1998-12-31
WO1993020078A1 (en) 1993-10-14
HUT70954A (en) 1995-11-28
ATE197051T1 (de) 2000-11-15
SK119194A3 (en) 1995-05-10
AU3917493A (en) 1993-11-08
DK0633886T3 (da) 2000-12-18
NO943655L (no) 1994-12-05
FI944602L (fi) 1994-10-03

Similar Documents

Publication Publication Date Title
ES2150941T3 (es) Aminas biciclicas-heterociclicas eficaces farmaceuticamente.
ES2092460T1 (es) Composicion donadora de oxido nitrico y procedimiento para el tratamiento de trastornos anales.
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
DE69534150D1 (de) Präsynaptische Neurotoxine gegen Migränekopfschmerzen
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
EP0706373A4 (en) TAXOL ENCLOSED IN LIPOSOMES AND METHOD OF USE
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
FI954130A0 (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
NO180334C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive difluorstatonanaloger
FI94354C (fi) Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
FR2581382B1 (fr) Derives n-(quinolyl) glycinamides, leur procede de preparation et leur application therapeutique en tant que psychotropes
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ATE27813T1 (de) N-substituierte 1-(4'-alkylsulfonylphenyl)-2amino-1,3-propanediol-derivate.
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
FI98456B (fi) Menetelmä terapeuttisesti aktiivisten 1-piperidinyylialkanoyyliaryylisulfonamidijohdannaisten valmistamiseksi
ZA845930B (en) 1-(4'-alkylthiophenyl)-2-amino-1,3-propanediol n-substituted derivatives
NO177705C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive ascorbinsyrederivater
ATE247963T1 (de) Medikament zur behandlung von glaukoma und ischämischer retinopathie
DK164987C (da) Anvendelse af spergualin eller et farmaceutisk acceptabelt salt deraf til fremstilling af et laegemiddel med transplantationsimmunitetsinhiberende og antiallergisk aktivitet
RU92016567A (ru) Производные тетразола и антиаллергическая композиция
SE9901273D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633886

Country of ref document: ES